{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:31:02Z","timestamp":1794267062308,"version":"4.9.0"},"reference-count":181,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:p>Despite &amp;gt;1 in 5 children taking prescription drugs in the United States, off-label drug use is common. To increase the study of drugs in children, regulatory bodies have enacted legislation to incentivize and require pediatric drug studies. As a result of this legislation, novel trial approaches, and an increase in personnel with pediatric expertise, there have been numerous advancements in pediatric drug development. With this review, we aim to highlight developments in pediatric pharmacology over the past 6 years for the most common disease processes that may be treated pharmacologically by the pediatric primary care provider. Using information extracted from label changes between 2018 and 2023, the published literature, and Clinicaltrials.gov, we discuss advances across multiple therapeutic areas relevant to the pediatric primary care provider, including asthma, obesity and related disorders, mental health disorders, infections, and dermatologic conditions. We highlight instances in which new drugs have been developed on the basis of a deeper mechanistic understanding of illness and instances in which labels have been expanded in older drugs on the basis of newly available data. We then consider additional factors that affect pediatric drug use, including cost and nonpharmacologic therapies. Although there is work to be done, efforts focused on pediatric-specific drug development will increase the availability of evidence-based, labeled guidance for commonly prescribed drugs and improve outcomes through the safe and effective use of drugs in children.<\/jats:p>","DOI":"10.1542\/peds.2023-064158","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T08:09:06Z","timestamp":1717661346000},"source":"Crossref","is-referenced-by-count":4,"title":["Pediatric Pharmacology for the Primary Care Provider: Advances and Limitations"],"prefix":"10.1542","volume":"154","author":[{"given":"Elizabeth J.","family":"Thompson","sequence":"first","affiliation":[{"name":"aDuke University Hospital, Durham, North Carolina"},{"name":"bDuke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles T.","family":"Wood","sequence":"additional","affiliation":[{"name":"aDuke University Hospital, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph P.","family":"Hornik","sequence":"additional","affiliation":[{"name":"aDuke University Hospital, Durham, North Carolina"},{"name":"bDuke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"issue":"19","key":"2024070102520907300_B1","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1001\/jama.2018.5690","article-title":"Trends in prescription medication use among children and adolescents\u2014United States, 1999\u20132014","volume":"319","author":"Hales","year":"2018","journal-title":"JAMA"},{"issue":"8","key":"2024070102520907300_B2","first-page":"776","article-title":"Off-label medication use in children, more common than we think: A systematic review of the literature","volume":"111","author":"Allen","year":"2018","journal-title":"J Okla State Med Assoc"},{"issue":"4","key":"2024070102520907300_B3","doi-asserted-by":"crossref","first-page":"e007283","DOI":"10.1161\/JAHA.117.007283","article-title":"Recommendations to enhance pediatric cardiovascular drug development: report of a multi-stakeholder think tank","volume":"7","author":"Torok","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"2024070102520907300_B4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0011-393X(01)80078-3","article-title":"Adverse drug events in children: the US food and drug administration perspective","volume":"62","author":"Rodriguez","year":"2001","journal-title":"Curr Ther Res Clin Exp"},{"issue":"7","key":"2024070102520907300_B5","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/jama.290.7.905","article-title":"Pediatric drug labeling: improving the safety and efficacy of pediatric therapies","volume":"290","author":"Roberts","year":"2003","journal-title":"JAMA"},{"issue":"5","key":"2024070102520907300_B6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1586\/ecp.11.43","article-title":"Innovative clinical trial design for pediatric therapeutics","volume":"4","author":"Laughon","year":"2011","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"2024070102520907300_B7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1542\/hpeds.2018-0168","article-title":"Off-label medication prescribing patterns in pediatrics: An update","volume":"9","author":"Yackey","year":"2019","journal-title":"Hosp Pediatr"},{"key":"2024070102520907300_B8","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1002\/jcph.1284","article-title":"Developmental changes in pharmacokinetics and pharmacodynamics","volume":"58","author":"van den Anker","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"2024070102520907300_B9","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/cpt.1332","article-title":"Renal clearance in newborns and infants: predictive performance of population-based modeling for drug development","volume":"105","author":"Wang","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"2024070102520907300_B10","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/jcph.294","article-title":"Predicting the \u201cFirst dose in children\u201d of CYP3A-metabolized drugs: evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young ages","volume":"54","author":"Strougo","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"2024070102520907300_B11","first-page":"262","article-title":"Developmental pharmacokinetics in pediatric populations","volume":"19","author":"Lu","year":"2014","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2024070102520907300_B12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jpeds.2017.08.011","article-title":"The need for pediatric drug development","volume":"192","author":"Ward","year":"2018","journal-title":"J Pediatr"},{"key":"2024070102520907300_B13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.curtheres.2019.02.001","article-title":"Global pediatric drug development","volume":"90","author":"Thomsen","year":"2019","journal-title":"Curr Ther Res Clin Exp"},{"key":"2024070102520907300_B14","author":"US Food and Drug Administration"},{"issue":"1","key":"2024070102520907300_B15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamapediatrics.2018.3416","article-title":"Completion rate and reporting of mandatory pediatric postmarketing studies under the US Pediatric Research Equity Act","volume":"173","author":"Hwang","year":"2019","journal-title":"JAMA Pediatr"},{"issue":"4","key":"2024070102520907300_B16","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3390\/pharmaceutics2040364","article-title":"Drug development for pediatric populations: regulatory aspects","volume":"2","author":"Zisowsky","year":"2010","journal-title":"Pharmaceutics"},{"key":"2024070102520907300_B17","author":"US Food and Drug Administration"},{"key":"2024070102520907300_B18","author":"European Medicines Agency"},{"issue":"3","key":"2024070102520907300_B19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.phrs.2011.01.016","article-title":"The development of medicines for children. Part of a series on pediatric pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni","volume":"64","author":"Rocchi","year":"2011","journal-title":"Pharmacol Res"},{"issue":"3","key":"2024070102520907300_B20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cpt.142","article-title":"Failed pediatric drug development trials","volume":"98","author":"Momper","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"2024070102520907300_B21","author":"European Medicine Agency"},{"key":"2024070102520907300_B22","author":"Child and Adolescent Health Measurement Initiative"},{"issue":"11","key":"2024070102520907300_B23","doi-asserted-by":"crossref","DOI":"10.1542\/pcco_book112_document001","article-title":"Top 25 pediatric diagnoses revisited","volume":"8","author":"American Academy of Pediatrics","year":"2013","journal-title":"AAP Pediatric Coding Newsletter"},{"issue":"5","key":"2024070102520907300_B24","doi-asserted-by":"crossref","first-page":"e1178","DOI":"10.1542\/peds.2015-0807","article-title":"Outpatient visits and medication prescribing for US children with mental health conditions","volume":"136","author":"Anderson","year":"2015","journal-title":"Pediatrics"},{"issue":"12","key":"2024070102520907300_B25","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1377\/hlthaff.2014.0832","article-title":"The rise in chronic conditions among infants, children, and youth can be met with continued health system innovations","volume":"33","author":"Perrin","year":"2014","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"2024070102520907300_B26","doi-asserted-by":"crossref","first-page":"e2022060640","DOI":"10.1542\/peds.2022-060640","article-title":"Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity","volume":"151","author":"Hampl","year":"2023","journal-title":"Pediatrics"},{"issue":"4","key":"2024070102520907300_B27","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/jamapediatrics.2019.5509","article-title":"Trends in pediatric primary care visits among commercially insured US children, 2008-2016","volume":"174","author":"Ray","year":"2020","journal-title":"JAMA Pediatr"},{"key":"2024070102520907300_B28","author":"Child and Adolescent Health Measruement Initiative"},{"key":"2024070102520907300_B29","author":"National Center for Health Statistics (NCHS)"},{"key":"2024070102520907300_B30","author":"US Food and Drug Administration"},{"key":"2024070102520907300_B31","author":"UpToDate, Inc"},{"issue":"11","key":"2024070102520907300_B32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1542\/pir.2018-0282","article-title":"Asthma","volume":"40","author":"Patel","year":"2019","journal-title":"Pediatr Rev"},{"issue":"2","key":"2024070102520907300_B33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding asthma phenotypes, endotypes, and mechanisms of disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"2024070102520907300_B34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/MCP.0000000000000434","article-title":"Precision medicine in asthma: linking phenotypes to targeted treatments","volume":"24","author":"Chung","year":"2018","journal-title":"Curr Opin Pulm Med"},{"issue":"4","key":"2024070102520907300_B35","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jaci.2016.06.061","article-title":"Asthma phenotypes in inner-city children","volume":"138","author":"Zoratti","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2024070102520907300_B36","author":"National Institute of Allergy and Infectious Diseases"},{"issue":"6","key":"2024070102520907300_B37","doi-asserted-by":"crossref","first-page":"e2021050286","DOI":"10.1542\/peds.2021-050286","article-title":"The 2020 focused updates to the NIH asthma management guidelines: key points for pediatricians","volume":"147","author":"Cloutier","year":"2021","journal-title":"Pediatrics"},{"issue":"3","key":"2024070102520907300_B38","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaci.2023.01.002","article-title":"Biologics in the treatment of asthma in children and adolescents","volume":"151","author":"Bacharier","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2024070102520907300_B39","doi-asserted-by":"crossref","first-page":"2333794x19891305","DOI":"10.1177\/2333794X19891305","article-title":"Childhood and adolescent obesity in the United States: A public health concern","volume":"6","author":"Sanyaolu","year":"2019","journal-title":"Glob Pediatr Health"},{"issue":"12","key":"2024070102520907300_B40","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jama.2020.14590","article-title":"Trends in obesity prevalence by race and hispanic origin-1999-2000 to 2017-2018","volume":"324","author":"Ogden","year":"2020","journal-title":"JAMA"},{"key":"2024070102520907300_B41","doi-asserted-by":"crossref","first-page":"101882","DOI":"10.1016\/j.eclinm.2023.101882","article-title":"Pharmacotherapy of obesity: an update on the available medications and drugs under investigation","volume":"58","author":"Chakhtoura","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"1","key":"2024070102520907300_B42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/MED.0000000000000587","article-title":"Pharmacotherapy in pediatric obesity: current evidence and landscape","volume":"28","author":"Singhal","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"2024070102520907300_B43","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1748-720X.2007.00119.x","article-title":"Trends in childhood obesity research: a brief analysis of NIH-supported efforts","volume":"35","author":"Huang","year":"2007","journal-title":"J Law Med Ethics"},{"issue":"2","key":"2024070102520907300_B44","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3892\/etm.2017.4597","article-title":"Identification of key genes and pathways associated with obesity in children","volume":"14","author":"Li","year":"2017","journal-title":"Exp Ther Med"},{"issue":"11","key":"2024070102520907300_B45","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1542\/pir.2021-005095","article-title":"Obesity in children","volume":"43","author":"Nagpal","year":"2022","journal-title":"Pediatr Rev"},{"key":"2024070102520907300_B46","author":"U.S. Food and Drug Administration"},{"key":"2024070102520907300_B47","author":"U.S. Food and Drug Administration"},{"key":"2024070102520907300_B48","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jpeds.2021.05.009","article-title":"Safety and efficacy of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity: A meta-analysis","volume":"236","author":"Ryan","year":"2021","journal-title":"J Pediatr"},{"issue":"5","key":"2024070102520907300_B49","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41591-018-0015-9","article-title":"MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency","volume":"24","author":"Cl\u00e9ment","year":"2018","journal-title":"Nat Med"},{"issue":"12","key":"2024070102520907300_B50","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2213-8587(20)30364-8","article-title":"Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials","volume":"8","author":"Cl\u00e9ment","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024070102520907300_B51","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.33549\/physiolres.934512","article-title":"Melanocortin pathways: suppressed and stimulated melanocortin-4 receptor (MC4R)","volume":"69","author":"Hainer","year":"2020","journal-title":"Physiol Res"},{"key":"2024070102520907300_B52","doi-asserted-by":"crossref","first-page":"120857","DOI":"10.1016\/j.lfs.2022.120857","article-title":"Structural analysis of setmelanotide binding to MC4R variants in comparison to wild-type receptor","volume":"307","author":"Hammad","year":"2022","journal-title":"Life Sci"},{"issue":"6","key":"2024070102520907300_B53","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/87551225221116010","article-title":"Setmelanotide: a novel targeted treatment for monogenic obesity","volume":"38","author":"Pressley","year":"2022","journal-title":"J Pharm Technol"},{"issue":"2","key":"2024070102520907300_B54","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/MED.0000000000000798","article-title":"Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity","volume":"30","author":"Trapp","year":"2023","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"6","key":"2024070102520907300_B55","doi-asserted-by":"crossref","first-page":"bvac057","DOI":"10.1210\/jendso\/bvac057","article-title":"Natural history of obesity due to POMC, PCSK1, and LEPR deficiency and the impact of setmelanotide","volume":"6","author":"Wabitsch","year":"2022","journal-title":"J Endocr Soc"},{"issue":"1","key":"2024070102520907300_B56","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1161\/HYPERTENSIONAHA.118.11673","article-title":"Prevalence of hypertension in children","volume":"73","author":"Bell","year":"2019","journal-title":"Hypertension"},{"issue":"3","key":"2024070102520907300_B57","doi-asserted-by":"crossref","first-page":"e20171904","DOI":"10.1542\/peds.2017-1904","article-title":"Clinical practice guideline for screening and management of high blood pressure in children and adolescents","volume":"140","author":"Flynn","year":"2017","journal-title":"Pediatrics"},{"issue":"10","key":"2024070102520907300_B58","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s00467-007-0573-4","article-title":"Treatment of hypertension in children and adolescents","volume":"24","author":"Lande","year":"2009","journal-title":"Pediatr Nephrol"},{"issue":"12 Pt 3","key":"2024070102520907300_B59","doi-asserted-by":"crossref","first-page":"205S","DOI":"10.1016\/S0895-7061(99)00103-X","article-title":"The renin-angiotensin-aldosterone system: a specific target for hypertension management","volume":"12","author":"Weir","year":"1999","journal-title":"Am J Hypertens"},{"issue":"7","key":"2024070102520907300_B60","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s00467-020-04788-w","article-title":"When should we start and stop ACEi\/ARB in paediatric chronic kidney disease?","volume":"36","author":"Chan","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"2024070102520907300_B61","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jpeds.2006.08.074","article-title":"Pharmacologic treatment of hypertension in children and adolescents","volume":"149","author":"Flynn","year":"2006","journal-title":"J Pediatr"},{"issue":"19","key":"2024070102520907300_B62","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1001\/jama.2019.4984","article-title":"Trends in levels of lipids and apolipoprotein b in US youths aged 6 to 19 years, 1999-2016","volume":"321","author":"Perak","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"2024070102520907300_B63","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11883-014-0482-5","article-title":"Familial hypercholesterolemia--epidemiology, diagnosis, and screening","volume":"17","author":"Singh","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"2024070102520907300_B64","volume-title":"PCSK9 Inhibitors","author":"Pokhrel","year":"2022"},{"issue":"8","key":"2024070102520907300_B65","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1542\/pir.2019-0053","article-title":"Hyperlipidemia","volume":"41","author":"Stewart","year":"2020","journal-title":"Pediatr Rev"},{"key":"2024070102520907300_B66","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1542\/peds.2009-2107C","article-title":"Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report","volume":"128 Suppl 5","author":"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents","year":"2011","journal-title":"Pediatrics"},{"key":"2024070102520907300_B67","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1542\/peds.146.1MA7.636","article-title":"Pediatric dyslipidemia screening by pediatricians and family medicine physicians: Current practices and future directions","volume":"146","author":"Sleeth","year":"2020","journal-title":"Pediatrics"},{"key":"2024070102520907300_B68","author":"Novartis Pharmaceuticals"},{"key":"2024070102520907300_B69","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1399-5448.2007.00327.x","article-title":"Type 2 diabetes in youth: rates, antecedents, treatment, problems and prevention","volume":"8","author":"Kaufman","year":"2007","journal-title":"Pediatr Diabetes"},{"issue":"1","key":"2024070102520907300_B70","first-page":"4","article-title":"A review of the treatment of type 2 diabetes in children","volume":"20","author":"Onge","year":"2015","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"8","key":"2024070102520907300_B71","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s11892-014-0508-y","article-title":"Obesity and type 2 diabetes in children: epidemiology and treatment","volume":"14","author":"Pulgaron","year":"2014","journal-title":"Curr Diab Rep"},{"key":"2024070102520907300_B72","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1399-5448.2009.00584.x","article-title":"Type 2 diabetes in children and adolescents","volume":"10","author":"Rosenbloom","year":"2009","journal-title":"Pediatr Diabetes"},{"issue":"2","key":"2024070102520907300_B73","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1542\/peds.2012-3494","article-title":"Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents","volume":"131","author":"Copeland","year":"2013","journal-title":"Pediatrics"},{"issue":"6","key":"2024070102520907300_B74","doi-asserted-by":"crossref","first-page":"e13177","DOI":"10.1111\/obr.13177","article-title":"GLP-1 agonists for obesity and type 2 diabetes in children: Systematic review and meta-analysis","volume":"22","author":"Chadda","year":"2021","journal-title":"Obes Rev"},{"key":"2024070102520907300_B75","author":"Eli Lilly and Company"},{"key":"2024070102520907300_B76","author":"Amylin Pharmaceuticals Inc"},{"key":"2024070102520907300_B77","author":"Eli Lilly and Company"},{"issue":"7","key":"2024070102520907300_B78","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40262-022-01140-3","article-title":"Effects of hepatic impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide","volume":"61","author":"Urva","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"2024070102520907300_B79","doi-asserted-by":"crossref","first-page":"e20192528","DOI":"10.1542\/peds.2019-2528","article-title":"Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents","volume":"144","author":"Wolraich","year":"2019","journal-title":"Pediatrics"},{"key":"2024070102520907300_B80","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3389\/fnhum.2015.00359","article-title":"Pathophysiology of ADHD and associated problems-starting points for NF interventions?","volume":"9","author":"Albrecht","year":"2015","journal-title":"Front Hum Neurosci"},{"issue":"81","key":"2024070102520907300_B81","first-page":"1","article-title":"Diagnostic experiences of children with attention-deficit\/hyperactivity disorder","author":"Visser","year":"2015","journal-title":"Natl Health Stat Rep"},{"issue":"2","key":"2024070102520907300_B82","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/15374416.2017.1417860","article-title":"Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents, 2016","volume":"47","author":"Danielson","year":"2018","journal-title":"J Clin Child Adolesc Psychol"},{"issue":"3","key":"2024070102520907300_B83","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1542\/pir.2020-000612","article-title":"Attention-deficit\/hyperactivity disorder","volume":"43","author":"Rajaprakash","year":"2022","journal-title":"Pediatr Rev"},{"issue":"3","key":"2024070102520907300_B84","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1089\/cap.2011.0090","article-title":"Parent perspectives on the decision to initiate medication treatment of attention-deficit\/hyperactivity disorder","volume":"22","author":"Coletti","year":"2012","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2024070102520907300_B85","author":"Purdue Pharma L.P."},{"key":"2024070102520907300_B86","author":"Tris Pharma Inc"},{"key":"2024070102520907300_B87","author":"Arbor Pharmaceuticals LLC"},{"key":"2024070102520907300_B88","author":"Corium"},{"key":"2024070102520907300_B89","author":"Noven Pharmaceuticals Inc"},{"key":"2024070102520907300_B90","author":"Patheon Puerto Rico Inc"},{"key":"2024070102520907300_B91","author":"Catalent Pharma Solutions LLC"},{"key":"2024070102520907300_B92","author":"Dainippon Sumitomo Pharma Co"},{"key":"2024070102520907300_B93","author":"Eli Lilly and Company"},{"key":"2024070102520907300_B94","author":"Forest Pharmaceuticals Inc"},{"key":"2024070102520907300_B95","author":"Otsuka Pharmaceutical Co"},{"key":"2024070102520907300_B96","author":"American Academy of Pediatrics"},{"key":"2024070102520907300_B97","author":"US Surgeon General"},{"issue":"2","key":"2024070102520907300_B98","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pedhc.2011.10.009","article-title":"Antipsychotic medication prescribing trends in children and adolescents","volume":"26","author":"Harrison","year":"2012","journal-title":"J Pediatr Health Care"},{"issue":"1","key":"2024070102520907300_B99","doi-asserted-by":"crossref","first-page":"7","DOI":"10.31887\/DCNS.2009.11.1\/krmerikangas","article-title":"Epidemiology of mental disorders in children and adolescents","volume":"11","author":"Merikangas","year":"2009","journal-title":"Dialogues Clin Neurosci"},{"issue":"2","key":"2024070102520907300_B100","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/camh.12575","article-title":"Differences in body mass index trajectories of adolescent psychiatric inpatients by sex, age, diagnosis and medication: an exploratory longitudinal, mixed effects analysis","volume":"28","author":"Anthony","year":"2023","journal-title":"Child Adolesc Ment Health"},{"issue":"6","key":"2024070102520907300_B101","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1111\/eip.12777","article-title":"High prevalence of metabolic alterations in Latin American patients at initial stages of psychosis","volume":"13","author":"Iruretagoyena","year":"2019","journal-title":"Early Interv Psychiatry"},{"key":"2024070102520907300_B102","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.schres.2019.07.022","article-title":"Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans","volume":"212","author":"Maciukiewicz","year":"2019","journal-title":"Schizophr Res"},{"issue":"2","key":"2024070102520907300_B103","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/dom.13522","article-title":"Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis","volume":"21","author":"Siskind","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2024070102520907300_B104","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/acps.12982","article-title":"One-year follow-up on liraglutide treatment for prediabetes and overweight\/obesity in clozapine- or olanzapine-treated patients","volume":"139","author":"Svensson","year":"2019","journal-title":"Acta Psychiatr Scand"},{"issue":"7","key":"2024070102520907300_B105","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1089\/cap.2017.0147","article-title":"Predictors and moderators of antipsychotic-related weight gain in the treatment of early-onset schizophrenia spectrum disorders study","volume":"28","author":"Taylor","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2024070102520907300_B106","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3389\/fpsyt.2018.00725","article-title":"Is obesity in young people with psychosis a foregone conclusion? Markedly excessive energy intake is evident soon after antipsychotic initiation","volume":"9","author":"Teasdale","year":"2018","journal-title":"Front Psychiatry"},{"issue":"8","key":"2024070102520907300_B107","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.acap.2021.04.031","article-title":"Trends in pediatric primary care visits during the coronavirus disease of 2019 pandemic","volume":"21","author":"Schweiberger","year":"2021","journal-title":"Acad Pediatr"},{"issue":"3","key":"2024070102520907300_B108","doi-asserted-by":"crossref","first-page":"e20181042","DOI":"10.1542\/peds.2018-1042","article-title":"Prescription medication use among children and adolescents in the United States","volume":"142","author":"Qato","year":"2018","journal-title":"Pediatrics"},{"issue":"1","key":"2024070102520907300_B109","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1542\/peds.2011-2879","article-title":"Trends of outpatient prescription drug utilization in US children, 2002-2010","volume":"130","author":"Chai","year":"2012","journal-title":"Pediatrics"},{"issue":"6","key":"2024070102520907300_B110","doi-asserted-by":"crossref","first-page":"e20170933","DOI":"10.1542\/peds.2017-0933","article-title":"Epidemiology and risk factors of infection in early childhood","volume":"141","author":"Vissing","year":"2018","journal-title":"Pediatrics"},{"issue":"2","key":"2024070102520907300_B111","doi-asserted-by":"crossref","first-page":"e2021053079","DOI":"10.1542\/peds.2021-053079","article-title":"COVID-19 and antibiotic prescribing in pediatric primary care","volume":"149","author":"Dutcher","year":"2022","journal-title":"Pediatrics"},{"key":"2024070102520907300_B112","author":"American Academy of Pediatrics"},{"key":"2024070102520907300_B113","author":"U. S. Food & Drug Administration"},{"issue":"3","key":"2024070102520907300_B114","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1542\/peds.2005-2022","article-title":"Expert committee recommendations for acne management","volume":"118","author":"Zaenglein","year":"2006","journal-title":"Pediatrics"},{"issue":"5","key":"2024070102520907300_B115","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jaad.2008.07.013","article-title":"Self-esteem and body satisfaction among late adolescents with acne: results from a population survey","volume":"59","author":"Dalgard","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2024070102520907300_B116","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2024070102520907300_B117","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/pde.12201","article-title":"Treatment of preadolescent acne in the United States: an analysis of nationally representative data","volume":"30","author":"Davis","year":"2013","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"2024070102520907300_B118","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1525-1470.2008.00790.x","article-title":"Differences in acne treatment prescribing patterns of pediatricians and dermatologists: an analysis of nationally representative data","volume":"25","author":"Yentzer","year":"2008","journal-title":"Pediatr Dermatol"},{"key":"2024070102520907300_B119","author":"Galderma"},{"key":"2024070102520907300_B120","author":"Galderma"},{"key":"2024070102520907300_B121","author":"Galderma"},{"key":"2024070102520907300_B122","author":"Galderma"},{"key":"2024070102520907300_B123","author":"USA TP"},{"key":"2024070102520907300_B124","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1542\/peds.2013-0490B","article-title":"Evidence-based recommendations for the diagnosis and treatment of pediatric acne","volume":"131","author":"Eichenfield","year":"2013","journal-title":"Pediatrics"},{"issue":"4","key":"2024070102520907300_B125","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2024070102520907300_B126","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1542\/pir.2016-0169","article-title":"Atopic Dermatitis","volume":"39","author":"Waldman","year":"2018","journal-title":"Pediatr Rev"},{"key":"2024070102520907300_B127","author":"American Academy of Pediatrics"},{"issue":"3","key":"2024070102520907300_B128","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jaad.2019.07.105","article-title":"Treatment patterns of pediatric patients with atopic dermatitis: a claims data analysis","volume":"82","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2024070102520907300_B129","doi-asserted-by":"crossref","first-page":"e527","DOI":"10.1542\/peds.2007-0289","article-title":"Atopic dermatitis in children in the United States, 1997-2004: visit trends, patient and provider characteristics, and prescribing patterns","volume":"120","author":"Horii","year":"2007","journal-title":"Pediatrics"},{"issue":"10290","key":"2024070102520907300_B130","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2024070102520907300_B131","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaci.2022.09.023","article-title":"Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies","volume":"151","author":"Guttman-Yassky","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2024070102520907300_B132","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jdin.2021.11.001","article-title":"A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis","volume":"6","author":"Katoh","year":"2021","journal-title":"JAAD Int"},{"issue":"10290","key":"2024070102520907300_B133","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"2024070102520907300_B134","author":"AbbVie Biotechnology Ltd"},{"key":"2024070102520907300_B135","author":"Incyte Corporation"},{"key":"2024070102520907300_B136","author":"Pfizer Labs"},{"key":"2024070102520907300_B137","author":"AbbVie"},{"key":"2024070102520907300_B138","author":"AbbVie"},{"key":"2024070102520907300_B139","author":"AbbVie"},{"key":"2024070102520907300_B140","author":"AbbVie"},{"key":"2024070102520907300_B141","author":"AbbVie"},{"key":"2024070102520907300_B142","author":"AbbVie"},{"key":"2024070102520907300_B143","author":"AbbVie"},{"key":"2024070102520907300_B144","author":"AbbVie"},{"key":"2024070102520907300_B145","author":"AbbVie"},{"key":"2024070102520907300_B146","author":"AbbVie"},{"key":"2024070102520907300_B147","author":"AbbVie"},{"key":"2024070102520907300_B148","author":"AbbVie"},{"key":"2024070102520907300_B149","author":"AbbVie"},{"key":"2024070102520907300_B150","author":"AbbVie"},{"key":"2024070102520907300_B151","author":"Pfizer"},{"key":"2024070102520907300_B152","author":"Pfizer"},{"key":"2024070102520907300_B153","author":"Pharma LEO"},{"key":"2024070102520907300_B154","author":"Pharma LEO"},{"key":"2024070102520907300_B155","author":"Pharma LEO"},{"key":"2024070102520907300_B156","author":"Pharma LEO"},{"key":"2024070102520907300_B157","author":"US Food and Drug Administration"},{"key":"2024070102520907300_B158","author":"American Academy of Pediatrics"},{"key":"2024070102520907300_B159","doi-asserted-by":"crossref","first-page":"101182","DOI":"10.1016\/j.conctc.2023.101182","article-title":"A point-of-care pharmacokinetic\/pharmacodynamic trial in critically ill children: study design and feasibility","volume":"35","author":"Thompson","year":"2023","journal-title":"Contemp Clin Trials Commun"},{"issue":"2","key":"2024070102520907300_B160","doi-asserted-by":"crossref","first-page":"e20190562","DOI":"10.1542\/peds.2019-0562","article-title":"Big data in the assessment of pediatric medication safety","volume":"145","author":"McMahon","year":"2020","journal-title":"Pediatrics"},{"issue":"1299","key":"2024070102520907300_B161","doi-asserted-by":"crossref","first-page":"n1299","DOI":"10.1136\/bmj.n1299","article-title":"On the road to recovery-the world\u2019s biggest COVID-19 treatment trial","volume":"373","author":"Stokel-Walker","year":"2021","journal-title":"BMJ"},{"key":"2024070102520907300_B162","doi-asserted-by":"crossref","first-page":"m1626","DOI":"10.1136\/bmj.m1626","article-title":"RECOVERY trial: the UK COVID-19 study resetting expectations for clinical trials","volume":"369","author":"Wilkinson","year":"2020","journal-title":"BMJ"},{"key":"2024070102520907300_B163","author":"US Food and Drug Administration"},{"issue":"1","key":"2024070102520907300_B164","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamapediatrics.2018.3227","article-title":"Duration of pediatric clinical trials submitted to the US food and drug administration","volume":"173","author":"Zimmerman","year":"2019","journal-title":"JAMA Pediatr"},{"issue":"9","key":"2024070102520907300_B165","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/jhm.13068","article-title":"Advancing pediatric medication safety using real-world data: current problems and potential solutions","volume":"18","author":"Antoon","year":"2023","journal-title":"J Hosp Med"},{"issue":"1","key":"2024070102520907300_B166","doi-asserted-by":"crossref","first-page":"e5695","DOI":"10.1002\/pds.5695","article-title":"Overview of global real-world data sources for pediatric pharmacoepidemiologic research","volume":"33","author":"Wharton","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"2024070102520907300_B167","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/10543406.2022.2152834","article-title":"Real world data (RWD) in pediatrics","volume":"33","author":"Lasky","year":"2023","journal-title":"J Biopharm Stat"},{"issue":"5","key":"2024070102520907300_B168","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s43441-023-00542-0","article-title":"Characterization of pediatric reports in the US food and drug administration adverse event reporting system from 2010-2020: A cross-sectional study","volume":"57","author":"Phan","year":"2023","journal-title":"Ther Innov Regul Sci"},{"issue":"6","key":"2024070102520907300_B169","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s43441-022-00410-3","article-title":"Health equity in pediatric drug development: Translating aspiration into operation","volume":"56","author":"Folayan","year":"2022","journal-title":"Ther Innov Regul Sci"},{"issue":"10","key":"2024070102520907300_B170","first-page":"1640","article-title":"Need for representation of pediatric patients with obesity in clinical trials","volume":"10","author":"Samuels","year":"2023","journal-title":"Children (Basel)"},{"issue":"10","key":"2024070102520907300_B171","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.3390\/pharmaceutics15102431","article-title":"Pediatric drug development: reviewing challenges and opportunities by tracking innovative therapies","volume":"15","author":"Domingues","year":"2023","journal-title":"Pharmaceutics"},{"issue":"775","key":"2024070102520907300_B172","first-page":"1","article-title":"Average wholesale price for prescription drugs: is there a more appropriate pricing mechanism?","author":"Gencarelli","year":"2002","journal-title":"NHPF Issue Brief"},{"key":"2024070102520907300_B173","doi-asserted-by":"crossref","first-page":"104681","DOI":"10.1016\/j.healthpol.2022.11.002","article-title":"Evidence on the effectiveness of policies promoting price transparency - a systematic review","volume":"134","author":"Joosse","year":"2023","journal-title":"Health Policy"},{"issue":"7","key":"2024070102520907300_B174","doi-asserted-by":"crossref","first-page":"e2325342","DOI":"10.1001\/jamanetworkopen.2023.25342","article-title":"Data sharing for pediatric clinical trials funded by the US National Institutes of Health","volume":"6","author":"Narang","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2024070102520907300_B175","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.curtheres.2018.12.001","article-title":"Pediatric drug development: challenges and opportunities","volume":"90","author":"Spadoni","year":"2018","journal-title":"Curr Ther Res Clin Exp"},{"issue":"3","key":"2024070102520907300_B176","doi-asserted-by":"crossref","first-page":"e230052","DOI":"10.1001\/jamahealthforum.2023.0052","article-title":"Association of primary care visit length with potentially inappropriate prescribing","volume":"4","author":"Neprash","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"6","key":"2024070102520907300_B177","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/ijpp.12565","article-title":"A population-based study of prescribing trends in a potentially vulnerable paediatric population from 1999 to 2012","volume":"27","author":"Sears","year":"2019","journal-title":"Int J Pharm Pract"},{"issue":"7","key":"2024070102520907300_B178","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaac.2020.09.023","article-title":"Trends in antipsychotic medication use in young privately insured children","volume":"60","author":"Bushnell","year":"2021","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2024070102520907300_B179","doi-asserted-by":"crossref","first-page":"644741","DOI":"10.3389\/fpsyt.2021.644741","article-title":"Psychotropic polypharmacy in the US pediatric population: a methodologic critique and commentary","volume":"12","author":"Zito","year":"2021","journal-title":"Front Psychiatry"},{"issue":"9","key":"2024070102520907300_B180","first-page":"1454","article-title":"State of the evidence for use of psychotropic medications in school-age youth","volume":"10","author":"Shahidullah","year":"2023","journal-title":"Children (Basel)"},{"issue":"4","key":"2024070102520907300_B181","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1542\/peds.2010-0082","article-title":"The Committee on D, Committee on Pediatric R. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations","volume":"125","author":"Shaddy","year":"2010","journal-title":"Pediatrics"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2023-064158\/1671769\/peds.2023-064158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2023-064158\/1671769\/peds.2023-064158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T06:55:42Z","timestamp":1732172142000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/154\/1\/e2023064158\/197473\/Pediatric-Pharmacology-for-the-Primary-Care"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":181,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,6,6]]},"published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2023-064158","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,6]]},"article-number":"e2023064158"}}